Chemotherapy management is a high-risk process, especially in oncology nursing, where errors can have serious consequences. Proactive risk analysis tools such as Failure Mode and Effects Analysis (FMEA) and its variant with Criticality Analysis (FMECA) are increasingly used to enhance safety.
Aim
To systematically review the effectiveness of FMEA/FMECA methodologies in identifying and mitigating risks within nursing processes related to chemotherapy preparation, administration, and management.
Methods
A systematic review was conducted following PRISMA 2020 guidelines. Literature was searched in PubMed and the Cochrane Library (as of February 9, 2025), including studies published from 2016 onwards in English, Italian, or Spanish. The quality of included studies was assessed using the Newcastle-Ottawa Scale, and a qualitative synthesis was performed.
Results
Thirteen studies met the inclusion criteria. FMEA/FMECA proved effective in identifying vulnerabilities in chemotherapy workflows, leading to the implementation of preventive and corrective actions. Improvements were observed in patient and staff safety, error reduction, process standardization, and integration of technological solutions.
Conclusion
FMEA/FMECA are valuable tools in proactively managing risks in oncology nursing. Their success depends on the active involvement of nursing staff and continuous training. Routine use is recommended to improve care quality and occupational safety.
FerraraMPascaleNCiavarellaM, et al.Is it still time for safety walkaround? Pilot project proposing a new model and a review of the methodology. Medicina (Kaunas)2024; 60(6): 903. https://doi.org/10.3390/medicina60060903
2.
UmarRMApikoglu-RabusSYumukPF. Significance of a clinical pharmacist-led comprehensive medication management program for hospitalized oncology patients. Int J Clin Pharm2020; 42(2): 652–661. https://doi.org/10.1007/s11096-020-00992-8
DonaldsonLJKelleyETDhingra-KumarN, et al.Medication without harm: who's third global patient safety challenge. Lancet2017; 389(10080): 1680–1681. https://doi.org/10.1016/s0140-6736(17)31047-4
AbbasinazariMZareh-ToranposhtiSHassaniA, et al.The effect of information provision on reduction of errors in intravenous drug preparation and administration by nurses in ICU and surgical wards. Acta Med Iran2012; 50(11): 771–777. https://acta.tums.ac.ir/index.php/acta/article/view/3991/3966
7.
MulacATaixsKHagesaetherE, et al.Severe and fatal medication errors in hospitals: findings from the Norwegian incident reporting system. Eur J Hosp Pharm2021; 28(Suppl 2): e56–e61. https://doi.org/10.1136/ejhpharm-2020-002298
8.
CavellGFMandaliyaD. Magnitude of error: a review of wrong dose medication incidents reported to a UK hospital voluntary incident reporting system. Eur J Hosp Pharm2021; 28(5): 260–265. https://doi.org/10.1136/ejhpharm-2019-001987
9.
HanJMHeoKNKimAJ, et al.Medication-related incidents in acute care hospitals among different age groups: an analysis of national patient safety report data. Pharmacoepidemiol Drug Saf2024; 33(6): e5819. https://doi.org/10.1002/pds.5819
10.
JessurunJGHunfeldNGMde RooM, et al.Prevalence and determinants of medication administration errors in clinical wards: a two-centre prospective observational study. J Clin Nurs2023; 32(1-2): 208–220. https://doi.org/10.1111/jocn.16215
ElliottRACamachoEJankovicD, et al.Economic analysis of the prevalence and clinical and economic burden of medication error in England. BMJ Qual Saf2021; 30(2): 96–105. https://doi.org/10.1136/bmjqs-2019-010206
LeonardJBMinhajFSKlein-SchwartzW. An analysis of fatal iatrogenic therapeutic errors reported to United States poison centers. Clin Toxicol (Phila)2021; 59(1): 53–60. https://doi.org/10.1080/15563650.2020.1766691
16.
WeberLLangebrakeCPicksakG, et al.Medication errors in cancer therapy: reports from German hospital pharmacists between 2008 and 2019. J Oncol Pharm Pract2023; 29(6): 1443–1453. https://doi.org/10.1177/10781552221135130
17.
AnjaleeJALRutterVSamaranayakeNR. Application of failure mode and effect analysis (FMEA) to improve medication safety: a systematic review. Postgrad Med J2021; 97(1145): 168–174. https://doi.org/10.1136/postgradmedj-2019-137484
18.
LiuHCZhangLJPingYJ, et al.Failure mode and effects analysis for proactive healthcare risk evaluation: a systematic liter-ature review. J Eval Clin Pract2020; 26(4): 1320–1337. https://doi.org/10.1111/jep.13317
19.
La RussaRFazioVFerraraM, et al.Proactive risk assessment through failure mode and effect analysis (FMEA) for haemodialysis facilities: a pilot project. Front Public Health2022; 24(10): 823680. https://doi.org/10.3389/fpubh.2022.823680
20.
Pueyo-LopezCSànchez-CuervoMVèlez-Dìaz-PallarèsM, et al.Healthcare failure mode and effect analysis in the chemotherapy preparation process. J Oncol Pharm Pract2021; 27(7): 1588–1595. https://doi.org/10.1177/1078155220962189
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021; 29(372): n71. https://doi.org/10.1136/bmj.n71
23.
PageMJMoherDBossuytPM, et al.PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ2021; 29: 372:n160. https://doi.org/10.1136/bmj.n160
FeemsterAAAugustinoMDuncanR, et al.Use of failure modes and effects analysis to mitigate potential risks prior to implementation of an intravenous compounding technology. Am J Health Syst Pharm2021; 78(14): 1323–1329. https://doi.org/10.1093/ajhp/zxab179
MattssonTOLipczakHPottegardA. Patient involvement in evaluation of safety in oral antineoplastic treatment: a failure mode and effects analysis in patients and health care professionals. Qual Manag Health Care2019; 28(1): 33–38. https://doi.org/10.1097/qmh.0000000000000199
28.
OuedraogoJMEl BarakaSAdadeCA, et al.Risk reduction in a cancer chemotherapy production unit: contribution of an automated drug dispensing system. J Oncol Pharm Pract2021; 27(4): 863–870. https://doi.org/10.1177/1078155220941060
29.
ChefchaouniACBoudinaYChennaqM, et al.Contribution of an anticancer drug compounding robot in reducing the risks of manual preparation in a hospital pharmacy unit specialized in oncology. J Oncol Pharm Pract2023; 29(6): 1334–1342. https://doi.org/10.1177/10781552221118846
30.
BourikaKKoutrasAKalofonosH, et al.Improvement of chemotherapy solutions production procedure in a hospital central chemotherapy preparation unit: a systematic risk assessment to prevent avoidable harm in cancer patients. Clin Med Insights Oncol2019; 10(13): 1179554919852933. https://doi.org/10.1177/1179554919852933
31.
BujaADe LucaGOttolitriK, et al.Using failure mode, effect and criticality analysis to improve safety in the cancer treatment prescription and administration process. J Pharm Policy Pract2023; 16(1): 9. https://doi.org/10.1186/s40545-023-00512-9
32.
LinSWangNRenB, et al.Use of failure mode and effects analysis (FMEA) for risk analysis of drug use in patients with lung cancer. Int J Environ Res Publ Health2022; 19(23): 15428. https://doi.org/10.3390/ijerph192315428
33.
CostaPCANunesVMAPimentaIDSF, et al.Failure mode and effect analysis in the preparation and dispensation of chemotherapy. Enfermería Glob2020; 58: 96–105. https://doi.org/10.6018/eglobal.389551
34.
WeberLSchulzeIJaehdeU. Using failure mode and effects analysis to increase patient safety in cancer chemotherapy. Res Soc Adm Pharm2022; 18(8): 3386–3393. https://doi.org/10.1016/j.sapharm.2021.11.009
El BarakaSChennaqMOudraogoJM, et al.Optimizing chemotherapy medication leftover management circuit in a centralized chemotherapy preparation unit: a comprehensive FMECA risk analysis and continuous improvement approach. J Oncol Pharm Pract2025; 31(1): 49–57. https://doi.org/10.1177/10781552231221450
37.
LeLMMReitterDHeS, et al.Safety analysis of occupational exposure of healthcare workers to residual contaminations of cytotoxic drugs using FMECA security approach. Sci Total Environ2017; 599–600: 1939–1944. https://doi.org/10.1016/j.scitotenv.2017.05.066
38.
BhirichNChefchaouniACEl MedkouriS, et al.Risk assessment of personnel exposure in a central cytotoxic preparation unit using the FMECA method. J Oncol Pharm Pract2023; 29(8): 1884–1892. https://doi.org/10.1177/10781552231153625
39.
Joly-MischlichTMaltaisSTètuA, et al.Application of the failure mode and effects analysis (FMEA) to identify vulnerabilities and opportunities for improvement prior to implementing a computerized prescription order entry (CPOE) system in a university hospital oncology clinic. J Oncol Pharm Pract2023; 29(1): 88–95. https://doi.org/10.1177/10781552211053253
40.
DinningCBranowickiPO’NeillJB, et al.Chemotherapy error reduction: a multidisciplinary approach to creating templated order set. J Pediatr Oncol Nur2005; 22(1): 20–30. https://doi.org/10.1177/1043454204272530
41.
ReinhardtHOttePEggletonAG, et al.Avoiding chemotherapy prescribing errors: analysis and innovative strategies. Cancer2019; 125(9): 1547–1557. https://doi.org/10.1002/cncr.31950
42.
Von GerichHMoenHBlockLJ, et al.Artificial intelligence -based technologies in nursing: a scoping literature review of the evidence. Int J Nurs Stud2022; 127: 104153. https://doi.org/10.1016/j.ijnurstu.2021.104153
43.
RadleyDCWassermanMROlshoLE, et al.Redection in medication errors in hospitals due to adoption of computerized provider order entry systems. J Am Med Inform Assoc2013; 20(3): 470–476. https://doi.org/10.1136/amiajnl-2012-001241
44.
SetarehSRabieiRMirzaeiHR, et al.Effects of guideline-based computerized provider order entry systems on the chemotherapy order process: a systematic review. Acta Inform Med2022; 30(1): 61–68. https://doi.org/10.5455/aim.2022.30.61-68
45.
HallKKShoemaker-HuntSHoffmanL, et al.Making healthcare safer III: a critical analysis of existing and emerging patient safety practices (Internet)Review. Agency for Healthcare Research and Quality (US), 2020. https://www.ncbi.nlm.nih.gov/books/NBK555526/ (accessed 30 July 2025).
46.
DeldicqueABourhisMCadotC, et al.Analyse des differentes methodes de controle des chimiotherapies: quel choix pour un centre hospitalier general?Le Pharmacien Hospitalier Clinicien2016; 51: 85–86. https://doi.org/10.1016/j.phclin.2016.01.054
47.
HonCYTeschkeKShenH, et al.Antineoplastic drug contamination in the urine of Canadian healthcare workers. Int Arch Occup Environ Health2015; 88(7): 933–941. https://doi.org/10.1007/s00420-015-1026-1
48.
Abu-AlhaijaDBakasTShaughnessyE, et al.The factors that influence chemotherapy exposure among nurses: an integrative review. Workplace Health Saf2023; 71(5): 212–227. https://doi.org/10.1177/21650799221140583
49.
AdadeCABenabbesMBelahcenMJ, et al.Centralization impact and cost-saving study in a Moroccan hospital's centralized unit of chemotherapy preparation. J Oncol Pharm Pract2020; 26(7): 1630–1636. https://doi.org/10.1177/1078155220901336
50.
WeingartSNSpencerJBuiaS, et al.Medication safety of five oral chemotherapies: a proactive risk assessment. J Oncol Pract2011; 7(1): 2–6. https://doi.org/10.1200/jop.2010.000064
51.
MichelettaFFerraraMBertozziG, et al.Proactive risk assessment through failure mode and effect analysis (FMEA) for perioperative management model of oral anticoagulant therapy: a pilot project. Int J Environ Res Publ Health2022; 19(24): 16430. https://doi.org/10.3390/ijerph192416430
